- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02916810
TMS for Symptom Reduction in Schizophrenia
March 21, 2023 updated by: L. Elliot Hong, University of Maryland, Baltimore
To test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry.
The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex).
The investigators predict that such modulation will correct abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory hallucination, and improve working memory/sustained attention performance.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Neuroimaging studies suggest that aberrant activities at specific brain regions such as sensory areas and language-related areas are related to psychosis symptoms including auditory and visual hallucination, delusion, and thought disorders.
Transcranial magnetic stimulation (TMS) provides a non-invasive means for altering brain electrical neural activity.
TMS has been approved by FDA for treatment of depression.
Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry.
Among psychotic symptoms, there are preliminary significant improvement in treatments of auditory hallucination using TMS with small samples, but those treatments are not robust in larger samples.
The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients.
The investigators aim to develop a TMS treatment method with a fMRI-defined treatment target area, where the TMS target is individually identified to maximize the TMS effects.
The identification method uses both the anatomical character and its functional relationship with auditory hallucination and other psychosis symptoms.
If the current target-identification successfully identified effective TMS target individually, the treatment efficacy will be significant improved and more patients will benefit from TMS treatment.
Study Type
Interventional
Enrollment (Anticipated)
130
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21228
- Recruiting
- University of Maryland, Baltimore
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 62 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and Female between ages 21-62
- Ability to give written informed consent (age 21 or above)
- For patient participants, Evaluation to Sign Consent (ESC) 10 or greater.
- Medication stability for 4 weeks (same drugs at same dosages)
Exclusion Criteria:
- Any history of seizures
- Any Family history of epilepsy in first degree relatives
- Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
- Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions.
- Taking > 400 mg clozapine/day
- Failed TMS screening questionnaire
- Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth,that cannot be safely removed.
- History of head injury with loss of consciousness over 10 minutes; history of brain surgery
- Can not refrain from using alcohol and/or marijuana 24 hours or more & cigarette smoking half and hour or more prior to experiments.
- Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self report; or by positive pregnancy test)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active rTMS stimulation
Real active rTMS stimulation.
|
Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
|
Sham Comparator: Sham rTMS stimulation
Sham repetitive TMS stimulation.
|
Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician's Questionnaire for Auditory Hallucinations (CQAH) is used to evaluate the treatment effect of rTMS on auditory hallucination in schizophrenia.
Time Frame: 8 weeks
|
The study will test whether the rTMS stimulations reduce auditory hallucination of schizophrenia after the last rTMS treatment session.
The CQAH will be used by an clinician to evaluate the auditory hallucination severity of schizophrenia patients before, during, and after the rTMS series.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Electroencephalogram (EEG) is used to evaluate the brain electrical activities that are corresponding to the treatment effect on auditory hallucination.
Time Frame: 8 weeks
|
The EEG recordings will be done before, during, and after the rTMS series.
|
8 weeks
|
Functional magnetic resonance imaging (fMRI) is used to evaluate the brain activities that are corresponding to the treatment effect on auditory hallucination.
Time Frame: 8 weeks
|
The fMRI scans will be done before, during, and after the rTMS series.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2016
Primary Completion (Anticipated)
July 1, 2025
Study Completion (Anticipated)
July 1, 2025
Study Registration Dates
First Submitted
June 28, 2016
First Submitted That Met QC Criteria
September 23, 2016
First Posted (Estimate)
September 27, 2016
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 21, 2023
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HP-00070464
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia and Related Disorders
-
Northwell HealthWinterlight LabsCompletedSchizophrenia and Related DisordersUnited States
-
Haukeland University HospitalRecruitingBipolar Disorder | Schizophrenia and Related DisordersNorway
-
Vanderbilt University Medical CenterCompletedSchizophrenia and Related DisordersUnited States
-
Örebro University, SwedenActive, not recruitingSchizophrenia and Related DisordersSweden
-
Fundación Pública Andaluza para la gestión de la...Completed
-
University of BernCompletedSchizophrenia and Related DisordersSwitzerland
-
Weill Medical College of Cornell UniversityUniversity of Catania; University of Stirling; Hunter College of The City University...CompletedSchizophrenia and Related DisordersUnited States
-
National Taiwan University HospitalRecruitingSchizophrenia and Related DisordersTaiwan
-
University of BernTerminatedSchizophrenia and Related DisordersSwitzerland
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Columbia University; Stanford University and other collaboratorsCompleted
Clinical Trials on Active rTMS stimulation
-
Tianjin Anding HospitalChinese Academy of SciencesEnrolling by invitationSchizophrenia Negative TypeChina
-
Albert Einstein Healthcare NetworkMassachusetts General Hospital; Weill Medical College of Cornell University; University... and other collaboratorsNot yet recruitingTraumatic Spinal Cord Injury | Tetraplegia/TetraparesisUnited States
-
University of MinnesotaCompletedTreatment Resistant DepressionUnited States
-
University of ArkansasTerminated
-
University of ManitobaCompleted
-
Shanghai Mental Health CenterXuhui Mental Health CenterRecruitingSchizophrenia | Cognitive Impairment | Repetitive Transcranial Magnetic Stimulation | Negative Symptoms in Schizophrenia | Dorsolateral Prefrontal CortexChina
-
University of Sao Paulo General HospitalUnknownMild Cognitive ImpairmentBrazil
-
University of AarhusCentral Denmark Region; Hammel Neurorehabilitation Centre and University Research...RecruitingConcussion, Mild | Post-Traumatic Headache | MTBI - Mild Traumatic Brain InjuryDenmark
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Coordenação de Aperfeiçoamento de... and other collaboratorsUnknownMyofascial Pain SyndromesBrazil